Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Roux

Showing results (241-250 of 313) with videos related to

Pageof 32
Sort By:
Lancet (London, England)|April 14, 2009
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trialDavid M Reid, Jean-Pierre Devogelaer, Kenneth Saag, et al.
Archives of Osteoporosis|January 25, 2011
Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medicationsNick Freemantle, Cyrus Cooper, Christian Roux, et al.
The Journal of Clinical Endocrinology and Metabolism|August 18, 2021
Prevalence of Enthesopathies in Adults With X-linked Hypophosphatemia: Analysis of Risk FactorsJulia Herrou, Axelle Salcion Picaud, Louis Lassalle, et al.
The EMBO Journal|January 17, 2016
Non-acidic activation of pain-related Acid-Sensing Ion Channel 3 by lipidsSébastien Marra, Romain Ferru-Clément, Véronique Breuil, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 15, 2022
Do Glucocorticoid Injections Increase the Risk of Knee Osteoarthritis Progression Over 5 Years?Augustin Latourte, Anne-Christine Rat, Abdou Omorou, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 7, 2006
Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factorsChristian Roux, Jean-Yves Reginster, Jacques Fechtenbaum, et al.
Joint Bone Spine|December 3, 2014
2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosisKarine Briot, Bernard Cortet, Christian Roux, et al.
Rheumatology (Oxford, England)|October 10, 2018
STAT3 gain of function: a new aetiology of severe rheumatic diseaseLisa Giovannini-Chami, Tiphanie P Vogel, Lisa R Forbes, et al.
Bone|October 9, 2007
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisPierre D Delmas, Michael R McClung, José R Zanchetta, et al.
Biochemical and Biophysical Research Communications|October 19, 2013
Chondrogenic potential of stem cells derived from adipose tissue: a powerful pharmacological toolChristian Roux, Didier F Pisani, Hédi Ben Yahia, et al.
Pageof 32

Showing results (241-250 of 313) with videos related to

Sort By:
Pageof 32
Lancet (London, England)|April 14, 2009
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trialDavid M Reid, Jean-Pierre Devogelaer, Kenneth Saag, et al.
Archives of Osteoporosis|January 25, 2011
Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medicationsNick Freemantle, Cyrus Cooper, Christian Roux, et al.
The Journal of Clinical Endocrinology and Metabolism|August 18, 2021
Prevalence of Enthesopathies in Adults With X-linked Hypophosphatemia: Analysis of Risk FactorsJulia Herrou, Axelle Salcion Picaud, Louis Lassalle, et al.
The EMBO Journal|January 17, 2016
Non-acidic activation of pain-related Acid-Sensing Ion Channel 3 by lipidsSébastien Marra, Romain Ferru-Clément, Véronique Breuil, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 15, 2022
Do Glucocorticoid Injections Increase the Risk of Knee Osteoarthritis Progression Over 5 Years?Augustin Latourte, Anne-Christine Rat, Abdou Omorou, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 7, 2006
Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factorsChristian Roux, Jean-Yves Reginster, Jacques Fechtenbaum, et al.
Joint Bone Spine|December 3, 2014
2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosisKarine Briot, Bernard Cortet, Christian Roux, et al.
Rheumatology (Oxford, England)|October 10, 2018
STAT3 gain of function: a new aetiology of severe rheumatic diseaseLisa Giovannini-Chami, Tiphanie P Vogel, Lisa R Forbes, et al.
Bone|October 9, 2007
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisPierre D Delmas, Michael R McClung, José R Zanchetta, et al.
Biochemical and Biophysical Research Communications|October 19, 2013
Chondrogenic potential of stem cells derived from adipose tissue: a powerful pharmacological toolChristian Roux, Didier F Pisani, Hédi Ben Yahia, et al.
Pageof 32